Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

Human Gene Therapy

Volumn 7, Issue 4, 1996, Pages 551-563

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; INTERLEUKIN 2; VACCINE;

ADENOVIRUS; ARTICLE; CANCER STAGING; CELL TRANSFER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; FEMALE; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; IRRADIATION; KIDNEY CARCINOMA; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; CLINICAL PROTOCOL; GENE THERAPY; GENE TRANSFER; GENETICS;

CLINICAL PROTOCOLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; TRANSFECTION; VACCINES;

EID: 0029872770     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.4-551     Document Type: Article

References (60)

1. Aoki, T., Tashiro, K., Miyatake, S.I., Kinashi, T., Nakano, T., Oda, Y., Kikuchi, H., and Honjo, T. (1992). Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89, 3850-3854.
2. Bakker, A.B.H., Schreurs, M.W.J., De Boer, A.J., Kawakami, Y., Rosenberg, S.A., Adema, G.J., and Figdor, C.G. (1994). Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005-1009.
3. Balch, C.M., Cascinelli, N., Drzewiecki, K.T., Eldh J., Mackie, R.M., McCarthy, W.H., McLeod, J.R., Morton, D.L., Seigier, H.F., Shaw H.M. Sim, F.H., Sober, A.J., Soong, S.J., Takematsu, H., Tonak, J., and Wong, J. (1992) A comparison of prognostic factors worldwide. In Cutaneous melanoma. C.M. Balch, A.N. Houghton, G.W. Milton, A.J. Sober, and S.J. Soong, eds. (Philadelphia: J.B. Lippincott Company), pp. 188-199.
4. Brichard, V., Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie P, and Boon, T. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489-495.
5. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149, 3627-3635.
6. Chen, L., Linsley, P.S., and Hellström, K.E. (1993). Costimulation of T cells for tumor immunity. Immunol. Today 14, 483-486.
7. Coulie, P.G., Brichard, V., Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Matteri, S., De Plaen, E., Lurquin, C., Szikora, J.P., Renauld, J.C., and Boon, T. (1994). A new gene coding for a differentiation antigen recognized by autologous cytoloytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42.
8. Cox, A.L., Skipper, J., Chen, Y., Henderson, R.A., Darrow, T.L., Shabanowitz, J., Engelhard, V.H., Hunt, D.F., and Slingluff, C.L. (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719.
9. Darrow, T.L., Slingluff, C.L., and Seigler, H.F. (1988). Autologous lymph node cell derived tumor-specific cytotoxic T cells for use in adoptive immunotherapy of human melanoma. Cancer 62, 84-91.
10. Degiovanni, G., Hainaut, P., Lahaye, T., Weynants, P., and Boon, T. (1990). Antigens recognized on a melanoma line by autologous cytotoxic T lymphocytes are also expressed on freshly collected tumor cells. Eur. J. Immunol. 20, 1865-68.
11. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H.L., Brose, K., Jackson, V., Hamada, H., Pardoll, D.M., and Mulligan, R.C. (1993). Vaccination with irradiated tumor cells engineered to secret murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl. Acad. Sci. USA 90, 3539-3543.
12. Dvorak, A.M., Mihm, M.C., Osage, J.E., and Dvorak, H.F. (1980). Melanoma. An ultrastructural study of the host inflammatory and vascular responses. J. Invest. Dermatol. 75, 388-393.
13. Fearon, E.R., Itaya, T., Hunt, B., Vogelstein, B., and Frost, P. (1988). Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 48, 2975-2980.
14. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.L., Simons, J.W., Karasuyama, H., Vogelstein, B., and Frost, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
15. Ferradini, L., Mackensen, A., Genevée, C., Bosq, J., Duvilland, P., Avril, M.F., and Hercend, T. (1993). Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J Clin. Invest. 91, 1183-1190.
16. Fujiwara, H., Shimizu, Y., Takai, Y., Wakamiya, N., Ueda, S., Karo, S., and Hamaoka, T. (1984). The augmentation of tumor-specific immunity by virus help: I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses. Eur. J. Immunol. 14, 171-175.
17. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. (1990a). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
18. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., and Gilboa, E. (1990b). Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50, 7820-7825.
19. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., and Pardoll, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
20. Grin-Jorgensen, C.M., Rigel, D.S., and Friedman, R.J. (1992). The worldwide incidence of malignant melanoma. In Cutaneous melanoma. C.M. Balch, A.N. Houghton, G.W. Milton, A.J. Sober, and S.J. Soong, eds. (Philadelphia: J.B. Lippincott Company), pp. 27-39.
21. Haddada, H., Ragot, T., Cordier, L., Duffour, M.T., and Perricaudet, M. (1993). Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum. Gene Ther. 4, 703-711.
22. Hersey, P., Edwards, A., Coates, A., Shaw, H., McCarthy, W.H., and Milton, G.W. (1987). Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol. Immunother. 25, 257-265.
23. + T cell-dependent tumor rejection. J. Exp. Med. 174, 1291-1298.
24. Houghton, A.N. and Balch, C.M. (1992). Treatment of advanced melanoma. In Cutaneous melanoma. C.M. Balch, A.N. Houghton, G.W. Milton, A.J. Sober, and S.J. Soong, eds. (Philadelphia: J.B. Lippincott Company), pp. 468-497.
25. Itoh, K., Platsoucas, C.D., and Balch, C.M. (1988). Autologous tumor-specific cytotoxic T lymphocyts in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168, 1419-1441.
26. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Rivoltini, L., Topalian, S.L., Miki, T., and Rosenberg, S.A. (1994). Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515-3519.
27. Lehner, B., Schlag, P., Liebrich, W., and Schirrmacher, V. (1990). Post-operative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine. Cancer Immunol. Immunother. 32, 173-178.
28. Ley, V., Langlade-Demoyen, P., Kourilsky, P., and Larsson-Sciard, E.L. (1991). Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 21, 851-854.
29. Liebrich, W., Schlag, P., Manasterski, M., Lehner, B., Stöhr, M., Möller, P., and Schirrmacher, V. (1991). In vitro and clinical characterization of a Newcastle disease virus-modified autologous tumor cell vaccine for treatment of colorectal patients. Eur. J. Cancer 27, 703-710.
30. Lindenmann, J. and Klein, P.A. (1967). Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126, 93-108.
31. Longstreth, J.D., Lea, C.S., and Kripke, M.L. (1992). Ultraviolet radiation and other putative causes of melanoma. In Cutaneous melanoma. C.M. Balch, A.N. Houghton, G.W. Milton, A.J. Sober, and S.J. Soong, eds. (Philadelphia: J.B. Lippincott Company), pp. 46-58.
32. Maass, G., Schmidt, W., Berger, M., Schilcher, F., Koszik, F., Schneeberger, A., Stingl, G., Birnstiel, M.L., and Schweighoffer, T. (1995). Priming of tumor-specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 92, 5540-5544.
33. Mackensen, A., Carcelain, G., Viel, S., Raynal, M.C., Michalaki, H., Triebel, F., Bsoq, J., and Hercend, T. (1994). Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93, 1397-1402.
34. Morton, D.L., Foshag, L.J., Hoon, D.S.B., Nizze, J.A., Wanek, L.A., Chang, C., Davtyan, D.G., Gupta, R.K., Elashoff, R., Irie, R.F. (1992). Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216, 463-482.
35. Nitta, T., Oksenberg, J.R., Rao, N.A., and Steinman, L. (1990). Predominant expression of T cell receptor Vα7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 249, 672.
36. Parkinson, D.R., Abrams, F.R., Wiernik, P.H., Rayner, A.A., Margolin, K.A., Van Echo, D.A., Sznol, M., Dutcher, J.P., Aronson, F.R., Doroshow, J.H. Atkins, M.B., and Hawkins, M.J. (1990). Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J. Clin. Oncol. 8, 1650-1656.
37. Perez, E.A., Scudder, S.A., Meyers, F.A., Tanaka, M.S., Paradise, C., and Gandara, D.R. (1991). Weekly 24-hour continuous infusion interleukin-2 for metastatic and renal cell carcinoma: A phase I study. J. Immunother. 10,57-62.
38. Pfeifer, J.D., Wick, M.J., Roberts, R.L., Findlay, K., Normark, S.J., and Harding, C.V. (1993). Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361, 359-362.
39. Porgador, A., Tzehoval E, Katz, A., Vadai, E., Revel, M., Feldman, M., and Eisenbach, L. (1992). Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679-3686.
40. Ralfkiaer, E., Hou-Jensen, K., Gatter, K.C., Drzewiecki, D.T., and Mason, D.Y. (1987). Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch. 410, 355-361.
41. Reintgen, S., Vollmer, R., Tso, C.Y., and Seigler, H.F. (1987). Prognosis for recurrent stage I malignant melanoma. Arch. Surg. 122, 1338-1342.
42. Rock, K.L., Gamble S., and Rothstein, L. (1990). Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249, 918-921.
43. Rosenberg, S.A., Lotze, M., Muul, L., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, J.T., Seipp, C.A., Simpson, C.G., and White, D.E. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897.
44. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Aebersold, P.M., Lineham, W.M., Seipp, C.A., and White D.E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
45. Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C., Simpson, C., Carter C., Bock, S., Schwartzentruber, D., Wei, J.P., and White, D.E. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676-1680.
46. Rosenstein, M., Ettinghausen, S.E., and Rosenberg, S.A. (1986). Extravasation of intervascular fluid mediated by the systemic administration of recombinant Interleukin-2. J. Immunol. 137, 1735-1742.
47. Schmidt, W., Schweighoffer, T., Herbst, E., Maass, G., Berger, M., Schilcher, F., and Birnstiel, M.L. (1995). Cancer vaccines: the interleukin-2 dosage effect. Proc Natl. Acad. Sci. USA 92, 4711-4714.
48. Sensi, M., Salvi, S., Castelli, C., Maccalli, C., Mazzocchi, A., Mortarini, R., Nicolini, G., Herlyn, M., Parmiani, G., and Anichini, A. (1993). T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR β chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J. Exp. Med. 178, 1231-1246.
49. Shimizu, Y., Fujiwara, H., Ueda, S., Wakamiya, N., Kato, S., and Hamaoka, T. (1984). The augmentation of tumor-specific immunity by virus help: II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T-cells. Eur. J. Immunol. 14, 839-843.
50. Siegel, J.P. and Puri, R.K. (1991). Interleukin-2 toxicity. J. Clin. Oncol. 9, 694-704.
51. Slingluff, C.L., Hunt, D.F., and Engelhard, V.H. (1994). Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol. 6, 733-740.
52. Steinman, R.M. (1991). The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296.
53. Strohal, R., Paucz, L., Pehamberger, H., and Stingl, G. (1994). T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V α specificities present in T-cells of normal human skin. Cancer Res. 54, 4734-4739.
54. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91, 9461-9465.
55. Topalian, S.L., Solomon, D., and Rosenberg, S.A. (1989). Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714-3725.
56. Van der Bruggen, P., Traversari, C., Cho;mez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
57. Weidmann, E., Elder, E.M., Trucco, M., Lotze, M.T., and Whiteside, T.L. (1994). Usage of T-cell receptor Vβ chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int. J. Cancer 54, 383-390.
58. Zatloukal, K., Schmidt, W., Cotten, M., Wagner, E., Stingl, G., and Birnstiel, M.L. (1993). Somatic gene therapy for cancer: The utility of transferrinfection in generating tumor vaccines. Gene 135, 199-207.
59. Zatloukal, K., Schneeberger, A., Berger, M., Schmidt, W., Koszik, F., Kutil, R., Cotten, M., Wagner, E., Buschle, M., Maass, G., Payer, E., Stingl, G., and Birnstiel, M.L. (1995). Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine: assessment of critical cellular and molecular parameters. J. Immunol. 154, 3406-3419.
60. Zatloukal, K., Wagner, E., Cotten, M., Phillips, S., Plank, C., Steinlein, P., Curiel, D.T., and Birnstiel, M.L. (1992). Transferrinfection: A highly efficient way to express gene constructs in eukariotic cells. Ann. N.Y. Acad. Sci. 660, 136-153.